Quick Facts: Erec Uses

• May help manage erectile dysfunction (ED), which is the inability to achieve or maintain an erection suitable for satisfactory sexual performance.
• Is an approved treatment option for pulmonary arterial hypertension (PAH) to improve exercise capacity.

---

What Erec Treats: Main Uses and Benefits

Erec is a medication approved to address specific medical conditions. Its primary therapeutic role involves the management of erectile dysfunction (ED). For adult males experiencing this condition, Erec may help support the ability to attain and sustain an erection when sexual stimulation occurs.

Erec is also an approved medication for treating pulmonary arterial hypertension (PAH). In this context, the drug may help relax the blood vessels in the lungs, which can help increase exercise ability and may help delay a decline in condition for adults with WHO Group I PAH. This medication is one available option within the current standard of care for these domains.

Erec (based on sildenafil for erectile dysfunction) is generally indicated for use by adult men aged 18 years and older who do not have documented contraindications. Eligibility is strictly defined by regulatory guidelines, which establish absolute prohibitions and restricted use populations.

Contraindications and Exclusions

Classification	Who Must Not Use Erec
Concomitant Medication	Patients using organic nitrates (e.g., nitroglycerin) in any form or guanylate cyclase stimulators (e.g., riociguat).
Absolute Health Status	Patients with a known hypersensitivity to the drug, or those who have had a recent stroke or heart attack (within 6 months).

Restricted Use Populations

Certain groups require a lower starting dose (e.g., 25 mg) due to slower drug clearance, as stated in regulatory labels:

• Older Adults (Age 65 years and older).
• Patients with severe renal impairment (creatinine clearance <30 mL/min).
• Patients with mild-to-moderate hepatic impairment; use in severe hepatic impairment is generally not recommended as it has not been studied.

Erec is not indicated for use in women or children for the treatment of erectile dysfunction.

Interactions with other medicines and products

Erec's interaction profile is documented in regulatory sources and primarily involves pharmacokinetic (PK) and pharmacodynamic (PD) mechanisms. The PK interactions are largely mediated by substances that alter the activity of the Cytochrome P450 3A4 (CYP3A4) enzyme, which metabolizes the active ingredient, sildenafil.

Formal Contraindications

Co-administration of Erec is formally prohibited with specific classes of medicines due to the risk of severe, additive adverse effects:

• Organic Nitrates or Nitric Oxide Donors: Contraindicated due to the high risk of potentiating hypotensive effects, potentially leading to a sharp drop in blood pressure.
• Guanylate Cyclase (GC) Stimulators (e.g., Riociguat): Prohibited due to the documented potential for symptomatic hypotension.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type	Interacting Substance/Class	Official Interaction Outcome
PK (Increased Exposure)	Strong CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole)	Significantly increases sildenafil plasma concentrations, which may require regulatory restrictions (e.g., Ritonavir is documented to increase exposure by approximately 11-fold).
PK (Reduced Exposure)	CYP3A4 Inducers (e.g., Bosentan)	Increases sildenafil clearance, resulting in decreased sildenafil plasma levels.
PD (Additive Effects)	Alpha-Blockers, Antihypertensives	Co-administration may lead to additive systemic blood pressure lowering effects, increasing the risk of symptomatic hypotension.

Other Documented Interactions

Food and supplements may also alter drug exposure. A high-fat meal can delay the time to maximum plasma concentration ( T max) and reduce maximum concentration ( C max). Consumption of Grapefruit Juice or Alcohol (Ethanol) may result in a modest increase in sildenafil plasma levels or enhance the vasodilatory effects, respectively.

Targeting PDE5 Enzyme and Amplifying the cGMP Signal

The core mechanism of Erec is the selective competitive inhibition of the enzyme Phosphodiesterase type 5 ( PDE5). This enzyme is naturally tasked with degrading the endogenous signaling molecule, cyclic Guanosine Monophosphate ( cGMP), within vascular smooth muscle cells. By blocking PDE5, the drug prevents the rapid breakdown of cGMP, thereby amplifying and prolonging the cellular signal initiated by the body's natural release of Nitric Oxide ( NO).

---

Cascade Leading to Vascular Smooth Muscle Relaxation

The sustained elevation of cGMP activates a protein kinase cascade that directly causes the specialized smooth muscle tissue in the walls of certain arteries to relax. This mechanism is stimulus-dependent, meaning it only enhances a pre-existing signal and cannot generate the initial response on its own. The resulting physiological effect is a sustained reduction in vascular resistance, resulting in increased localized blood flow.

---

Mechanism Limitations and Selectivity

While Erec is highly selective for PDE5, it exhibits some lesser cross-inhibition of the related enzyme PDE6 found in the retina. Functionally, the drug's mechanism is limited in scenarios where the upstream NO release is functionally compromised or where there is structural damage to the target vasculature, preventing the necessary smooth muscle response.

How to Use Erec: Official Administration Guidelines

Erec, containing sildenafil, is used according to distinct protocols depending on the condition being addressed. The medication is primarily delivered through the oral route, but an intravenous (IV) formulation is also used for specific circumstances within the Pulmonary Arterial Hypertension (PAH) management setting.

---

Administration Scope

Feature	Details
Dosing Schedule (Regimens)	For Erectile Dysfunction (ED): Initial oral dose is 50 mg. The dose may range from 25 mg to 100 mg. For PAH (Oral): Standard dose is 20 mg (tablet or suspension). For PAH (IV): Standard dose is 10 mg bolus injection, equivalent to the 20 mg oral dose.
Frequency and Timing	For ED: Taken as needed, up to once per day. For PAH: Taken three times a day (TID), administered approximately 4 to 6 hours apart.
Timing in Relation to Meals	Can be taken with or without food. Taking the ED tablet with a high-fat meal may lead to a delayed onset of action.
Special Procedural Conditions	The oral suspension requires reconstitution with water and must be shaken well prior to administration. The IV form is reserved for PAH patients temporarily unable to tolerate oral intake.

---

Population-Specific Considerations

A lower starting dose of 25 mg for ED is generally considered for certain populations. This includes older adults (aged 65 years or older), as well as patients who present with severe renal impairment or hepatic impairment. For the chronic PAH regimen, if a dose is missed, patients should take only the next scheduled dose as planned.

These instructions define the structured, two-part protocol for Erec usage: an intermittent, activity-dependent pattern for ED and a chronic, scheduled pattern for PAH, both governed by established dosage limits.

Research Evidence / Overview of Studies for Erec

---

Evidence for Use in Erectile Dysfunction (ED)

The evidence base for sildenafil in managing erectile dysfunction (ED) was studied for in numerous scientific settings. Research has primarily involved randomized, double-blind, placebo-controlled trials (RCTs) over short-term periods, typically four to twelve weeks. These studies explored outcomes reflecting daily functioning or activity level, specifically measuring patient-reported changes in the ability to achieve and maintain an erection, and success rates for sexual intercourse attempts.

Researchers monitored changes in scores on standard questionnaires used to assess erectile function. Findings describe patterns observed in the studies, and data show patterns related to these measured outcomes when compared to placebo groups. Long-term extension studies, lasting up to four years, were applied in studies examining patient-reported experiences regarding use patterns over time.

Evidence for Use in Pulmonary Arterial Hypertension (PAH)

Erec was evaluated in a different set of clinical trials for the treatment of pulmonary arterial hypertension (PAH), a condition marked by functional limitations. These trials were typically short-term, randomized studies lasting about 12 to 16 weeks.

The research examined outcomes monitoring physiological strain or stress and outcomes reflecting daily functioning or activity level. A primary focus was the 6-Minute Walk Distance (6MWD), a measure of exercise capacity. Research described patterns related to the distance covered when comparing the sildenafil groups to the placebo groups in the short term. Other research examined Time to Clinical Worsening (TTCW), tracking the time interval until events such as a patient needing hospitalization were observed.

Long-Term Studies and Follow-Up Data

For both approved conditions, patients often transitioned into long-term extension studies to track sustained changes. However, the existing studies provide limited information for long-term outcomes concerning the overall impact on patient survival across all study designs, and the certainty remains low regarding these extended results based solely on the current data.

Evidence in Specific Patient Populations

Sildenafil was studied for specific populations outside the main trial cohorts.

Subgroup Studies in Adult Comorbidities

For ED, studies specifically examined subgroups of adult males who have diabetes mellitus and hypertension. Research exploring short-term symptom changes in these groups reported findings describing group patterns, not personal outcomes.

Research in Pediatric Patients

Sildenafil was evaluated in pediatric patients (children aged 1 to 17 years) with PAH. While research highlights changes measured during the study period for functional capacity, the evidence derived from settings with varying symptom burdens also included reports where findings were mixed regarding effects and risks. Long-term extension data in this population show patterns related to varying effects, particularly concerning the risk of adverse events, that may vary by the dose used. The long-term effects are not fully established in this young population.

Research Gaps and Areas of Uncertainty

One key research limitation is that while studies in PAH report how symptoms evolved in the observed populations, the follow-up durations were limited in many pivotal trials. Data for rarer comorbidities were generally excluded from primary trials. For pediatric PAH, the subgroup findings are uncertain concerning optimal dosage, reinforcing that evidence highlights what is known — and what is still uncertain.

Key Studies & References

1. Oral Sildenafil in the Treatment of Erectile Dysfunction: A Double-Blind, Placebo-Controlled Study

Common questions about Erec (FAQ)

---

Q: What exactly is Erec used for?

Official regulatory documents state the drug is indicated for two primary uses. These are the treatment of Erectile Dysfunction (ED) in adult men and the treatment of Pulmonary Arterial Hypertension (PAH) in men and women to improve exercise capacity.

Q: Is Erec the same type of medicine as others for this condition?

Erec is classified in official documents as a Selective Phosphodiesterase-5 (PDE5) Inhibitor. This classification describes the specific biological target and mechanism of action, making it similar in class to other medicines used for the same condition.

Q: How long does Erec usually take to start working?

Studies show that maximum levels of the drug in the blood are usually reached within a median time of 60 minutes after taking it by mouth while fasting. The time frame for absorption is typically between 30 and 120 minutes.

Q: What is the typical time frame for Erec's effects to last?

Regulatory data indicates the drug is cleared from the body with a half-life of approximately three to five hours. Based on clinical studies, the effects may be observed for up to four hours, although the intensity of the response may begin to diminish after two hours.

Q: Is Erec meant to be a short-term or long-term treatment?

Official regulatory documents describe two different ways to use the medicine. For one approved condition (ED), the regimen is described as 'as needed,' meaning intermittent use. For the other approved condition (PAH), the drug is used on a scheduled, chronic basis.

Q: Is it possible for Erec to stop working over time?

Clinical studies included long-term extension phases to monitor the drug's sustained effects over periods up to four years. Official regulatory documents do not explicitly state a definitive risk of tolerance developing or the loss of long-term efficacy.

Q: Can Erec be used with common painkillers like ibuprofen?

Regulatory-based interaction screening suggests there is no known clinically significant interaction between the active ingredient and the common over-the-counter painkiller ibuprofen.

Q: Can Erec interact with multivitamins or herbal supplements?

Official product information primarily focuses on interactions with prescription drugs, Grapefruit Juice, and Alcohol. The official product information notes that some herbal products or multivitamins may contain ingredients that could potentially affect how the medicine is processed by the body.

Q: Is it safe to use Erec while taking medication for high cholesterol?

Official product information does not list common high cholesterol medications, such as statins, as formal contraindications. However, regulatory information notes that a small number of people who experienced certain serious adverse effects in studies also had high cholesterol.

Q: Can Erec be used by young adults?

Official information indicates the drug is intended for use by adults. For one condition, the approved starting regimen is generally established for patients up to 65 years of age. The drug is approved for use in certain pediatric patients with Pulmonary Arterial Hypertension (PAH), but not for the ED indication.

Q: Is Erec available as a generic medicine yet?

According to official drug registries, the active ingredient in Erec, known as sildenafil, is available as a generic prescription medicine.

Q: Where can I find the official clinical trial results for Erec?

Official results from completed clinical trials are generally published on government registries, such as ClinicalTrials.gov. These results are also referenced within the detailed regulatory documents submitted to agencies like the FDA or EMA.

Q: What happens when Erec is used at the same time as certain antibiotics?

Regulatory labeling warns about using Erec with strong CYP3A4 inhibitors. These are drugs that slow down how the body breaks down the medicine, potentially leading to increased drug levels. Regulatory documents indicate that increased drug levels resulting from these inhibitors may warrant a lower starting dose or restricted use.

Q: Why does the official information for Erec mention certain groups should not use it?

Regulatory documents mention exclusions to prevent a severe drop in blood pressure when the drug is used with certain heart medications (like nitrates). They also aim to avoid an increased risk of severe adverse events in patients with specific health conditions, such as a recent heart attack or stroke.

Q: Does Erec affect fertility?

Studies referenced in official product information, specifically nonclinical data from animal studies, showed no impairment of fertility. Limited research in men suggests on-demand use does not substantially affect general measures of sperm quality.

How to Store and Dispose of Erec?

Strict storage and disposal requirements for this medication are defined in official regulatory documents to ensure stability and safety.

Official Storage Requirements

Condition	Specific Requirement
Temperature Limit	Do not store above 30°C.
Protection	Store in the original package to protect the tablets from moisture.
Container	Keep in the container it came in, tightly closed.
Child Safety	Must be kept out of the reach and sight of children.

Official Disposal Instructions

Disposal must adhere strictly to local, regional, and national regulations. The medication must not be disposed of with household garbage or poured down a drain or toilet. Care must be taken to avoid environmental release, ensuring that disposal practices prevent the product from reaching the sewage system or ground.